Supplement: MilliporeSigma Sees Opportunity in Continuous Processing
From the GEN Sounds of Science Podcast
Why CAR-T Therapies Don’t Work for Everyone Yet
Selecting the Best Type of T Cells for CAR-T May be Key to the Overall Efficacy of the Therapies
Cell-Centered: Scientists Embrace Cell-Replacement Therapy for Type 1 Diabetes
Forming Beta Cells from Stem Cells
GEN Roundup: Multiplex Immunoassays Bring the Array, Not the Disarray
Get Multiplex Immunoassay Advice from GEN's Expert Panel
For full access to this article login to GEN Select now.
Optimizing the Delivery of Peptide-Based Therapeutics
Despite Processing Advantages, Peptides Pose Serious Delivery Challenges
- Interest in nonnatural peptide drugs has waxed and waned over the past 30 years. The science has been fascinating, but delivery and pharmacokinetic issues remain. During the 1990s, Affymax popularized libraries of short peptides immobilized on inert substrates, but these peptides never led to novel therapeutic molecules or ...
Not registered yet? Please fill out the form below and enjoy complimentary access to this and an exclusive collection of premium content and personalization features as a GEN Select insider. Learn More.
Get GEN Select Access Now
- Do not put any letters or characters here if you are not a spy program.